European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Three decades of neurocysticercosis mandatory notification in a Brazilian endemic region: clinical evolution and severity patterns.","authors":"Tissiana Marques de Haes, Thales Pardini Fagundes, Trajano Aguiar Pires Gonçalves, Osvaldo Massaiti Takayanagui","doi":"10.1007/s10096-026-05555-9","DOIUrl":"10.1007/s10096-026-05555-9","url":null,"abstract":"<p><strong>Background: </strong>Neurocysticercosis (NCC) is the leading cause of late-onset epilepsy in endemic regions, yet long-term data on severe forms remain limited. This study analyzed temporal trends in severe NCC over three decades following mandatory notification in a high-incidence region of Brazil.</p><p><strong>Methods: </strong>This retrospective population-based study included Neurocysticercosis cases reported from January 1995 to September 2024 in a high-incidence endemic area of São Paulo State, Brazil. Confirmed NCC cases were reclassified as intracranial hypertension syndrome (IHS) or other clinical presentations (epileptic, meningeal, asymptomatic). Clinical, neuroimaging, and cerebrospinal fluid data were analyzed. Multivariable logistic regression identified factors associated with severe disease.</p><p><strong>Results: </strong>Of 518 reported cases, 465 confirmed NCC cases were included. In the first decade (1991-2000, n = 262), 13.4% (35/262) were severe. Between these periods (2001-2010, n = 125), a steady decline in total incidence was observed. In the most recent period (2011-2020, n = 78), the proportion of severe cases rose to 65.4% (51/78). Meningeal manifestations were associated with increased severity risk (OR = 2.99; 95%CI: 1.81-4.94), whereas epileptic (OR = 0.30; 95%CI: 0.18-0.48) and asymptomatic presentations (OR = 0.21; 95%CI: 0.11-0.40) were protective. Neurosurgical procedures were required in 79.4% of severe cases.</p><p><strong>Conclusions: </strong>Despite declining overall incidence, the increasing proportion of severe NCC (intracranial hypertension) likely reflects late-stage diagnoses of long-standing infections that remained asymptomatic for decades. This trend suggests a 'catch-up' effect in detecting complex cases through improved neuroimaging, even as primary prevention programs successfully reduce new infections. .</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3149-3158"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden burden of leprosy in incarcerated populations in northeast Brazil: active case detection and serological assessment.","authors":"Thatiane Silva de Lucena, Lorena Covre Galani, Luize Dianin Barbosa, Gabriela Ferreira Dias, Jaci Maria Santana, Filipe Rocha Lima, Marco Andrey Cipriani Frade","doi":"10.1007/s10096-026-05578-2","DOIUrl":"10.1007/s10096-026-05578-2","url":null,"abstract":"<p><strong>Background: </strong>Leprosy remains a public health challenge in Brazil's Northeast, where prison overcrowding may facilitate transmission. Limited data exist on leprosy screening strategies in incarcerated populations.</p><p><strong>Methods: </strong>This observational, cross-sectional study was conducted at Baldomero Cavalcante Male Penitentiary in Maceió, Alagoas, Brazil. A total of 915 inmates were approached using the Leprosy Suspicion Questionnaire (LSQ) as an active case-finding tool. Neurodermatological examinations were performed on 260 participants, and serological testing for anti-PGL-I (IgM) and anti-Mce1A antibodies (IgA, IgM, IgG) was conducted on 244 plasma samples using indirect ELISA.</p><p><strong>Results: </strong>Of 842/915 returned questionnaires (92%), 240/842 (28.5%) were positive in the LSQ. Clinical examination revealed 8 new leprosy cases among 260/842 evaluated inmates with positive and negative LSQ, yielding an overall new case detection rate (NCDR) of 3.08%, which increased to 6.52% among symptomatic individuals. All diagnosed patients were classified as having multibacillary disease, with 100% presenting some grade of physical disability at diagnosis, and 75% LSQ were positive (p = 0.0249), while only 34.1% in the non-leprosy group. Anti-Mce1A IgM showed 37.7% seropositivity rate, and 19.9% for anti-PGL-I among clinically unaffected individuals. IgA (100%), IgM (37.5%), and IgG (25%) anti-Mce1A antibodies were positive in the leprosy group.</p><p><strong>Conclusions: </strong>The LSQ may be effective as a screening tool. The study confirms significant underdiagnosis of leprosy in prison populations and highlights that anti-Mce1A serology showed higher positivity among diagnosed cases than anti-PGL-I, particularly for the detection of early-stage and neural forms of the disease. These findings support enhanced active surveillance strategies in high-risk populations to achieve leprosy elimination goals.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3205-3215"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is less always more? Ceftazidime/avibactam alone or in combination to treat infections caused by Pseudomonas aeruginosa: a retrospective observational multi-centre cohort study.","authors":"Pietro Valsecchi, Marta Colaneri, Andrea Lombardi, Simona Biscarini, Cecilia Azzarà, Alessandra Bandera, Nicolò Corti, Paolo Bonfanti, Leonardo Francesco Rezzonico, Giovanna Travi, Silvia Pontiggia, Stefania Piconi, Arianna Lippi, Mario Tumbarello, Matteo Giovanni Lupi, Angelo Pan, Giacomo Casalini, Spinello Antinori, Andrea Gori, Alessandra Calabresi, Guido Chichino, Virginia Valeria Ferretti, Giulia Gambini, Catherine Klersy, Raffaele Bruno","doi":"10.1007/s10096-026-05599-x","DOIUrl":"10.1007/s10096-026-05599-x","url":null,"abstract":"<p><strong>Purpose: </strong>In vitro and in vivo studies suggest adding a second agent to ceftazidime/avibactam (CZA) to enhance bactericidal activity against Pseudomonas aeruginosa (PA). Nevertheless, evidence supporting this practice is scarce.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of patients admitted to 9 Italian hospitals with microbiologically confirmed PA infection and treated with CZA alone or in combination from 01/01/2015 to 31/12/2021. The primary endpoint was 14-day clinical cure. Secondary endpoints were 28-day all-cause mortality, 56-day microbiological failure, 56-day infection relapse, and emergence of CZA resistance. A generalized linear model extended to the binomial family, with identity link, weighted for IPTW (inverse probability of treatment weighting), was fitted to compare the two groups for 14-day clinical cure. Results were reported in terms of risk difference (RD) and 90% Confidence Interval (90%CI).</p><p><strong>Results: </strong>Eighty-seven patients with infection due to PA were included; 17 were treated with CZA monotherapy, and 70 with combination therapy with CZA plus another anti-pseudomonal agent. Sequential organ failure assessment was significantly higher (median 6 [3-9]) in the combination group compared to monotherapy (median 3 [1-5]; p = 0.049). After weighting patients according to the IPTW, CZA monotherapy did not reach the clinical equipoise to combination therapy in terms of 14-day clinical cure (RD -0.28, 90% CI -0.41 to -0.14). No significant risk difference between groups was found for any of the secondary endpoints.</p><p><strong>Conclusion: </strong>Our findings suggest that combination therapy with CZA for treating PA infections may provide some clinical benefit over monotherapy despite the absence of a definitive survival advantage.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3217-3227"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular epidemiology and pharmacokinetic-pharmacodynamic analysis of Neisseria gonorrhoeae strains in Northern Spain.","authors":"María Del Rosario Almela-Ferrer, María Carmen Nieto-Toboso, Elisabeth Montoya-Azpeitia, Josefina López-de Munain, Leonora Hernández-Ragpa, Inigo Gorostiza, Alicia Rodríguez-Gascón, Mikel Urrutikoetxea-Gutiérrez, Andrés Canut-Blasco, Sofía Ibarra-Ugarte, José Luis Díaz de Tuesta-Del Arco, Ramón Cisterna-Cancer, Miren Basaras-Ibarzabal","doi":"10.1007/s10096-026-05591-5","DOIUrl":"10.1007/s10096-026-05591-5","url":null,"abstract":"<p><strong>Purpose: </strong>To analyse the epidemiology, antimicrobial susceptibility and molecular diversity of Neisseria gonorrhoeae isolates recovered in 2016-2017 at a tertiary hospital in northern Spain, and to perform a seven-year pharmacokinetic/pharmacodynamic (PK/PD) evaluation using susceptibility data from previous studies conducted in the same hospital setting.</p><p><strong>Methods: </strong>A total of 231 non-duplicated isolates from 227 patients were studied. Antimicrobial susceptibility was determined by MIC gradient strip tests and molecular typing was performed by NG-MAST v2.0. Epidemiological variables were analysed, and considering the MIC distribution of the isolates, the cumulative fraction of response (CFR) for relevant antimicrobials was estimated.</p><p><strong>Results: </strong>Most infections occurred in men (80.5%), particularly among men who have sex with men (50.3%), with the highest incidence in patients aged 25-34 years. All isolates were susceptible to ceftriaxone and cefixime (100%), while susceptibility to azithromycin remained above 95% throughout the study period. In contrast, ciprofloxacin resistance remained high, ranging from 46.2% to 72.7% over the seven-year period. PK/PD analysis showed that CFR values ≥ 90% were achieved only with cephalosporins. Molecular typing identified 91 STs, including 15 previously undescribed STs. Six genogroups accounted for 51.9% of isolates and were associated with distinct epidemiological and resistance patterns.</p><p><strong>Conclusion: </strong>Ceftriaxone remains the preferred empirical treatment option for gonococcal infection. The favourable PK/PD performance observed for cefixime supports its activity against the studied isolates, although current treatment recommendations continue to prioritize ceftriaxone, particularly for extragenital infections; whereas ciprofloxacin should not be recommended for empirical use because of persistently high resistance rates. Continued molecular and antimicrobial resistance surveillance is essential for monitoring the emergence and dissemination of NG-MAST genogroups associated with antimicrobial resistance and for guiding future treatment strategies.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3169-3180"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of sonication to the microbiology diagnosis of periprosthetic joint infection: Retrospective study of real-world data.","authors":"Alia Barthel, Stéphane Klein, Lucas Niglis, Cyril Boeri, Emilie Talagrand-Reboul, François Severac, Jeannot Gaudias, Jean-Yves Jenny, Pierre Boyer, Cécile Ronde-Oustau","doi":"10.1007/s10096-026-05575-5","DOIUrl":"10.1007/s10096-026-05575-5","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the progress made in the treatment of periprosthetic joint infections, identifying the causative pathogen remains a challenge. Optimal antibiotic therapy requires a confirmed diagnosis, which relies on two positive cultures for the same microorganism. Even though both can produce consistent results, there is little data on the combination of sonication fluid culture (SFC) with standard fluid and tissue cultures for the microbiology diagnosis. We hypothesized that this combination could increase the number of confirmed microbiology diagnoses.</p><p><strong>Methods: </strong>This was retrospective, descriptive, single-centre study of consecutive patients who underwent a complete change of their hip or knee prosthesis between January 2019 and September 2021 due to a suspected infection. We expected that at least 5% of patients would have the infectious role of a micro-organism confirmed with sonication. The effect of prior antibiotic therapy was analysed on a subset of patients.</p><p><strong>Results: </strong>The analysis involved 223 patients with PJI diagnosis, 73 of whom had received antibiotics. The rate of confirmed microbiology diagnosis confirmed by one single positive sample culture plus SFC was 13.5% [9.6-18.6]. The rate was not significantly different in patients who had received antibiotic therapy (p = 0.960).</p><p><strong>Conclusion: </strong>According to our results, sonication could improve the rate of confirmed microbiology diagnosis of a PJI in our study, both in patients who previously received antibiotic therapy and in patients who had not yet been treated. This could make it a useful supplement to periprosthetic sampling in current practice.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3037-3044"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.","authors":"Amit Kumar, Adesh Kumar, Ashu Tyagi, Raj Singh, Myank Uday Charaya","doi":"10.1007/s10096-026-05577-3","DOIUrl":"10.1007/s10096-026-05577-3","url":null,"abstract":"<p><strong>Purpose: </strong>Bloodstream infections (BSIs) remain a major cause of morbidity and mortality worldwide and continue to represent a substantial challenge to modern healthcare systems. These infections arise when pathogenic microorganisms gain access to the bloodstream, triggering systemic inflammatory responses that may progress to sepsis, septic shock, multi-organ dysfunction, and death. This review provides a comprehensive overview of the historical development, epidemiology, pathogenesis, diagnosis, treatment, and future perspectives of BSIs. The major bacterial, fungal, viral, and parasitic pathogens associated with BSIs are discussed, with particular emphasis on their virulence attributes, mechanisms of immune evasion, antimicrobial resistance, and clinical significance.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted using peer-reviewed publications, clinical guidelines, surveillance reports, and systematic reviews published between 2010 and mid-2026. Evidence related to bacterial, fungal, viral, and parasitic bloodstream pathogens, host-pathogen interactions, diagnostic modalities, antimicrobial resistance mechanisms, and emerging therapeutic and diagnostic innovations was critically evaluated and integrated.</p><p><strong>Results: </strong>BSIs continue to impose a substantial healthcare burden, driven by increasing antimicrobial resistance, delayed diagnosis, and diverse pathogen-specific virulence mechanisms. Bacterial pathogens remain the predominant cause of BSIs, whereas Candida species represent the leading fungal agents. Advances in molecular diagnostics, metagenomic sequencing, biomarker-guided testing, and artificial intelligence-assisted analyses have substantially improved rapid pathogen detection and therapeutic decision-making. Precision medicine, genomic surveillance, and novel antimicrobial agents show considerable promise for enhancing clinical management and addressing multidrug-resistant infections.</p><p><strong>Conclusion: </strong>Bloodstream infections remain a major global health challenge due to their complex pathogenesis, increasing antimicrobial resistance, and high associated mortality. Improving patient outcomes requires early and accurate pathogen identification, prompt initiation of targeted antimicrobial therapy, effective antimicrobial stewardship, and continuous epidemiological surveillance. The integration of next-generation diagnostics, artificial intelligence-assisted pathogen detection, genomic surveillance, and precision medicine has the potential to transform BSI diagnosis and management by enabling rapid, individualized therapeutic interventions.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"2939-2987"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: \"Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing\".","authors":"Isheeka Lohana, Bhoomeeka Jayramdass","doi":"10.1007/s10096-026-05563-9","DOIUrl":"10.1007/s10096-026-05563-9","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3275-3276"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.","authors":"Paloma Gijón, Teresa Aldámiz, Ana Isabel Ramos-Lisbona, Flor Valenzuela, Cristina Rincón, Raquel Carrillo, Patricia Muñoz, Maria Jesus Ruiz-Serrano","doi":"10.1007/s10096-026-05570-w","DOIUrl":"10.1007/s10096-026-05570-w","url":null,"abstract":"<p><strong>Background: </strong>The World Health Organization emphasizes tuberculosis preventive treatment (TPT) as key to TB elimination. Implementation faces risk-benefit and adherence challenges. We implemented a structured TPT protocol at Hospital Gregorio Marañón with telephone support, personalized selection of currently available regimens, and toxicity management.</p><p><strong>Objective: </strong>To assess the structured TPT protocol in achieving complete preventive treatment (CPT) and identify factors associated with non-completion (NCPT).</p><p><strong>Methods: </strong>Retrospective analysis of a prospective cohort (2017-2024) of adults referred to the TB Unit. All causes of TPT were included per Spanish guidelines, except people living with HIV, who are followed in a separate clinic. Demographics, comorbidities, and outcomes were prospective collected. Univariate and multivariable logistic regression were used to identify predictors.</p><p><strong>Results: </strong>Of 554 patients, 542 (97.8%) initiated TPT: close TB contacts (37.6%), immunosuppression (27.9%), and indications for immunomodulatory therapy (34.5%). Overall CPT was 86.5% (80.3% in those > 75 years; 90.7% in ages 35-54). Cancer predicted NCPT (aOR 2.25; 95% CI 1.21-4.21; p = 0.011). Among 73 NCPT cases, toxicity was the main cause (42.5%), followed by voluntary withdrawal (27.4%), social problems (20.5%, mainly in young immigrants), intercurrent disease (9.6%, notably cancer). Polypharmacy (aOR 2.51; 95% CI 1.13-5.60; p = 0.023) and inflammatory disease (aOR 2.25; 95% CI 1.06-4.75; p = 0.034) independently predicted toxicity-related NCPT.</p><p><strong>Conclusions: </strong>The structured TPT protocol was associated with high CPT rates (86.5%), with excellent safety. Cancer predicted NCPT, polypharmacy and inflammatory disease predicted toxicity leading to NCPT. Similar studies are needed to compare our results.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3057-3067"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MUREAPLEXE: A multiplex recombinant antigen-based ELISA expanding the serological detection spectrum of urogenital mycoplasmas.","authors":"Sarra Abassi, Safa Boujemaa, Imen Chniba, Sabrina Zidi, Nadine Khadraoui, Behija Mlik, Wassim Y Almawi, Boutheina Ben Abdelmoumen Mardassi","doi":"10.1007/s10096-026-05566-6","DOIUrl":"10.1007/s10096-026-05566-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to improve the serological identification of urogenital mycoplasmas through the development of MUREAPLEXE, a recombinant protein-based multiplex ELISA allowing the simultaneous and specific detection of antibodies against Metamycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum.</p><p><strong>Methods: </strong>Genes encoding the major surface antigens Vaa and P120' of M. hominis, MBA3 of U. parvum and MBA8 of U. urealyticum were cloned into the prokaryotic expression vector pGEX-4T-1 and expressed in E. coli BL21. Recombinant GST-fusion proteins were purified by affinity chromatography using Glutathione-Sepharose 4B beads and were used to optimize an indirect multiplex ELISA. Both assays were subsequently evaluated using 162 patient sera that had been previously characterized by indirect immunofluorescence (IIF) and Western blot analysis.</p><p><strong>Results: </strong>Relative to IIF, both ELISA assays demonstrated high sensitivity. All tested sera showed reactivity with their corresponding recombinant antigens. Statistical analyses demonstrated a significant correlation between the two ELISA tests. However, MUREAPLEXE demonstrated markedly higher specificity.</p><p><strong>Conclusion: </strong>Given its high sensitivity and specificity for the simultaneous serological identification of M. hominis, U. parvum, and U. urealyticum, MUREAPLEXE may provide a robust and reliable complementary tool for the monitoring of urogenital mycoplasmas.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3135-3148"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on detection technologies for Mycoplasma pneumoniae.","authors":"Huanhuan Wu, Fang Jiang, Siyu Tian","doi":"10.1007/s10096-026-05594-2","DOIUrl":"10.1007/s10096-026-05594-2","url":null,"abstract":"<p><p>Mycoplasma pneumoniae (M. pneumoniae) is a primary pathogen responsible for community-acquired pneumonia (CAP), particularly prevalent among children and adolescents. The recent global resurgence of infection cases, coupled with the rapid dissemination of macrolide-resistant M. pneumoniae (MRMP), underscores the critical clinical need for rapid and precise diagnostic technologies. This article systematically reviews the evolutionary trajectory of detection technologies, covering the transition from traditional culture and serological testing to modern molecular diagnostic techniques. It critically analyzes emerging platforms, including isothermal amplification, CRISPR/Cas-based diagnostics, microfluidic chips, and biosensors. It explores their potential in facilitating point-of-care testing (POCT) and simultaneous antimicrobial resistance profiling. Despite continuous technological advancements, challenges remain regarding the differentiation between active infection and colonization, as well as the balancing of cost-effectiveness. The future of M. pneumoniae diagnostics lies in the deep integration of multidisciplinary biotechnologies with artificial intelligence, aiming to construct intelligent \"sample-to-answer\" solutions to optimize clinical antimicrobial stewardship.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":"3003-3017"},"PeriodicalIF":3.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148445262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}